RICHMOND, Va., Apr 25, 2003 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq:INSM) a leading developer of pharmaceutical products for the treatment of metabolic and endocrine diseases with unmet medical needs, will announce first quarter financial results Friday, May 2.
The Company will host a conference call on Friday, May 2, at 11:00 a.m. Eastern Time (10:00 a.m. Central Time). Company management will conduct the call that will highlight the improved performance expectations of the company and the upcoming pivotal Phase III trial with rhIGF-I/rhIGFBP-3.
To participate in the conference call dial 800-915-4836 (domestic) or 973-317-5319 (international). The call will be webcast live through Insmed's corporate website: www.insmed.com.
A telephonic replay of the call will be available for one week at 800-428-6051 (domestic) or 973-709-2089 (international), passcode: 290087. A web replay of the call will be available through the corporate website beginning at 10:00 a.m.
About Insmed Incorporated
Insmed Incorporated is a biopharmaceutical company focused on the development of drug candidates for the treatment of metabolic diseases with unmet medical needs. For further information about Insmed and rhIGF-I/rhIGFBP-3, please visit the company's corporate website at www.insmed.com.
Insmed Incorporated
Baxter Phillips, III (Investor Relations), 804/565-304
bphillips@insmed.com
